Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies

Molecular Therapy

Volumn 27, Issue 3, 2019, Pages 650-660

  Gardner, Matthew R ^a   Fetzer, Ina ^a   Kattenhorn, Lisa M ^b   Davis Gardner, Meredith E ^a   Zhou, Amber S ^a   Alfant, Barnett ^a   Weber, Jesse A ^a   Kondur, Hema R ^a   Martinez Navio, Jose M ^c   Fuchs, Sebastian P ^c   Desrosiers, Ronald C ^c   Gao, Guangping ^d   Lifson, Jeffrey D ^e   Farzan, Michael ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

10 1074; 3BNC117; AAV; ADA; anti drug antibodies; bNAbs; broadly neutralizing antibodies; HIV 1; NIH45 46; PGT121

Indexed keywords

10 1074; 3 BNC 117; ADENO ASSOCIATED VIRUS VECTOR; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; NEUTRALIZING ANTIBODY; NIH 45 46; PGT 121; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; HALF LIFE TIME; IMMUNOGENICITY; INDIAN; INFECTION PREVENTION; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMAL; DEPENDOPARVOVIRUS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM;

ANIMALS; ANTIBODIES, NEUTRALIZING; DEPENDOVIRUS; HIV-1; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; MACACA MULATTA;

EID: 85060544627     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2019.01.004     Document Type: Article

References (54)

1. Burton, D.R., Mascola, J.R., Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16 (2015), 571–576.
2. Gautam, R., Nishimura, Y., Pegu, A., Nason, M.C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K., et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533 (2016), 105–109.
3. Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M. Jr., Lifson, J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
4. Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, K.E., Chang, H.W., Shekhar, K., Gupta, S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
5. Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E.F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T.Y., et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23 (2017), 185–191.
6. Scheid, J.F., Horwitz, J.A., Bar-On, Y., Kreider, E.F., Lu, C.-L., Lorenzi, J.C.C., Feldmann, A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535 (2016), 556–560.
7. Bar, K.J., Sneller, M.C., Harrison, L.J., Justement, J.S., Overton, E.T., Petrone, M.E., Salantes, D.B., Seamon, C.A., Scheinfeld, B., Kwan, R.W., et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N. Engl. J. Med. 375 (2016), 2037–2050.
8. Lynch, R.M., Boritz, E., Coates, E.E., DeZure, A., Madden, P., Costner, P., Enama, M.E., Plummer, S., Holman, L., Hendel, C.S., et al., VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med., 7, 2015, 319ra206.
9. Ledgerwood, J.E., Coates, E.E., Yamshchikov, G., Saunders, J.G., Holman, L., Enama, M.E., DeZure, A., Lynch, R.M., Gordon, I., Plummer, S., et al., VRC 602 Study Team. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182 (2015), 289–301.
10. Johnson, P.R., Schnepp, B.C., Zhang, J., Connell, M.J., Greene, S.M., Yuste, E., Desrosiers, R.C., Clark, K.R., Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15 (2009), 901–906.
11. Balazs, A.B., Ouyang, Y., Hong, C.M., Chen, J., Nguyen, S.M., Rao, D.S., An, D.S., Baltimore, D., Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 20 (2014), 296–300.
12. Balazs, A.B., Chen, J., Hong, C.M., Rao, D.S., Yang, L., Baltimore, D., Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481 (2011), 81–84.
13. Martinez-Navio, J.M., Fuchs, S.P., Pedreño-López, S., Rakasz, E.G., Gao, G., Desrosiers, R.C., Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol. Ther. 24 (2016), 76–86.
14. Saunders, K.O., Wang, L., Joyce, M.G., Yang, Z.-Y., Balazs, A.B., Cheng, C., Ko, S.Y., Kong, W.P., Rudicell, R.S., Georgiev, I.S., et al. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J. Virol. 89 (2015), 8334–8345.
15. Fuchs, S.P., Martinez-Navio, J.M., Piatak, M. Jr., Lifson, J.D., Gao, G., Desrosiers, R.C., AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity. PLoS Pathog., 11, 2015, e1005090.
16. Haynes, B.F., Gilbert, P.B., McElrath, M.J., Zolla-Pazner, S., Tomaras, G.D., Alam, S.M., Evans, D.T., Montefiori, D.C., Karnasuta, C., Sutthent, R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366 (2012), 1275–1286.
17. Bonsignori, M., Pollara, J., Moody, M.A., Alpert, M.D., Chen, X., Hwang, K.-K., Gilbert, P.B., Huang, Y., Gurley, T.C., Kozink, D.M., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86 (2012), 11521–11532.
18. Desrosiers, R.C., Protection against HIV Acquisition in the RV144 Trial. J. Virol. 91 (2017), e00905–e00917.
19. Bournazos, S., Klein, F., Pietzsch, J., Seaman, M.S., Nussenzweig, M.C., Ravetch, J.V., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
20. Hessell, A.J., Hangartner, L., Hunter, M., Havenith, C.E., Beurskens, F.J., Bakker, J.M., Lanigan, C.M., Landucci, G., Forthal, D.N., Parren, P.W., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
21. Gardner, M.R., Kattenhorn, L.M., Kondur, H.R., von Schaewen, M., Dorfman, T., Chiang, J.J., Haworth, K.G., Decker, J.M., Alpert, M.D., Bailey, C.C., et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519 (2015), 87–91.
22. Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J.F., Halper-Stromberg, A., Gnanapragasam, P.N., Spencer, D.I., Seaman, M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109 (2012), E3268–E3277.
23. Fuchs, S.P., Martinez-Navio, J.M., Gao, G., Desrosiers, R.C., Recombinant AAV Vectors for Enhanced Expression of Authentic IgG. PLoS ONE, 11, 2016, e0158009.
24. Klein, F., Diskin, R., Scheid, J.F., Gaebler, C., Mouquet, H., Georgiev, I.S., Pancera, M., Zhou, T., Incesu, R.B., Fu, B.Z., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153 (2013), 126–138.
25. Nishimura, Y., Shingai, M., Willey, R., Sadjadpour, R., Lee, W.R., Brown, C.R., Brenchley, J.M., Buckler-White, A., Petros, R., Eckhaus, M., et al. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J. Virol. 84 (2010), 4769–4781.
26. Krishna, M., Nadler, S.G., Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes. Front. Immunol., 7, 2016, 21.
27. Gaudinski, M.R., Coates, E.E., Houser, K.V., Chen, G.L., Yamshchikov, G., Saunders, J.G., Holman, L.A., Gordon, I., Plummer, S., Hendel, C.S., et al., VRC 606 Study Team. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. PLoS Med., 15, 2018, e1002493.
28. Gardner, M.R., Farzan, M., Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr. Opin. HIV AIDS 12 (2017), 294–301.
29. Fuchs, S.P., Desrosiers, R.C., Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol. Ther. Methods Clin. Dev., 3, 2016, 16068.
30. Mingozzi, F., High, K.A., Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
31. Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., Herzog, R.W., Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105 (2005), 4226–4234.
32. Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121 (2013), 2224–2233.
33. Hoshino, M., Yoshio, T., Onishi, S., Minota, S., Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Mod. Rheumatol. 22 (2012), 532–540.
34. Emi Aikawa, N., de Carvalho, J.F., Artur Almeida Silva, C., Bonfá, E., Immunogenicity of Anti-TNF-α agents in autoimmune diseases. Clin. Rev. Allergy Immunol. 38 (2010), 82–89.
35. Lu, Y., Song, S., Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc. Natl. Acad. Sci. USA 106 (2009), 17158–17162.
36. Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A., Herzog, R.W., Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest. 111 (2003), 1347–1356.
37. Ziegler, R.J., Lonning, S.M., Armentano, D., Li, C., Souza, D.W., Cherry, M., Ford, C., Barbon, C.M., Desnick, R.J., Gao, G., et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of α-galactosidase A and the induction of immune tolerance in Fabry mice. Mol. Ther. 9 (2004), 231–240.
38. Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., Herzog, R.W., Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 104 (2004), 969–977.
39. Zhong, G., Wang, H., Bailey, C.C., Gao, G., Farzan, M., Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells. eLife, 5, 2016, e18858.
40. Martino, A.T., Suzuki, M., Markusic, D.M., Zolotukhin, I., Ryals, R.C., Moghimi, B., Ertl, H.C., Muruve, D.A., Lee, B., Herzog, R.W., The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117 (2011), 6459–6468.
41. Zhu, J., Huang, X., Yang, Y., The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest. 119 (2009), 2388–2398.
42. Adriouch, S., Franck, E., Drouot, L., Bonneau, C., Jolinon, N., Salvetti, A., Boyer, O., Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. Front. Microbiol., 2, 2011, 199.
43. + Treg. Blood 125 (2015), 2937–2947.
44. Mueller, C., Chulay, J.D., Trapnell, B.C., Humphries, M., Carey, B., Sandhaus, R.A., McElvaney, N.G., Messina, L., Tang, Q., Rouhani, F.N., et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Invest. 123 (2013), 5310–5318.
45. Nayak, S., Cao, O., Hoffman, B.E., Cooper, M., Zhou, S., Atkinson, M.A., Herzog, R.W., Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J. Thromb. Haemost. 7 (2009), 1523–1532.
46. Platt, E.J., Bilska, M., Kozak, S.L., Kabat, D., Montefiori, D.C., Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83 (2009), 8289–8292.
47. Takeuchi, Y., McClure, M.O., Pizzato, M., Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 82 (2008), 12585–12588.
48. Wei, X., Decker, J.M., Liu, H., Zhang, Z., Arani, R.B., Kilby, J.M., Saag, M.S., Wu, X., Shaw, G.M., Kappes, J.C., Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002), 1896–1905.
49. Derdeyn, C.A., Decker, J.M., Sfakianos, J.N., Wu, X., O'Brien, W.A., Ratner, L., Kappes, J.C., Shaw, G.M., Hunter, E., Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74 (2000), 8358–8367.
50. Platt, E.J., Wehrly, K., Kuhmann, S.E., Chesebro, B., Kabat, D., Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998), 2855–2864.
51. Scinicariello, F., Engleman, C.N., Jayashankar, L., McClure, H.M., Attanasio, R., Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 111 (2004), 66–74.
52. Gardner, M.R., Fellinger, C.H., Prasad, N.R., Zhou, A.S., Kondur, H.R., Joshi, V.R., Quinlan, B.D., Farzan, M., CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. J. Virol. 90 (2016), 7822–7832.
53. Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 (2005), 10108–10125.
54. Mueller, C., Ratner, D., Zhong, L., Esteves-Sena, M., Gao, G., Production and discovery of novel recombinant adeno-associated viral vectors. Current Protoc. Microbiol., Chapter 14, 2012, Unit 14D.1.